Clinical trials: sponsored by Boehringer Ingelheim
Stroke
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment within 4.5 hours of symptom…
- Trial name
- NCT05401149
- Testing
- rt-PA
- Where
- China
- Volunteers
- 3,058 people
- Sponsor
- Boehringer Ingelheim
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
All-Case Surveillance of Ofev in Patients With IPF in Japan
This is a non-interventional study based on new data collection to gather real-world information (i.e., data under routine medical practice) on safety and effectiveness of the Ofev® Capsules treatment.
- Trial name
- NCT02607722
- Testing
- Nintedanib
- Where
- Japan
- Volunteers
- 10,117 people
- Sponsor
- Boehringer Ingelheim
Neoplasm
A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)
The primary objective of this trial is: Part A To determine the Maximum tolerated dose (MTD) and/or the recommended dose (RD) of BI 891065 monotherapy for further development in Asian patients with advanced solid tumours Part B…
- Trial name
- NCT04138823
- Testing
- BI 891065
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient…
- Trial name
- NCT05870956
- Testing
- Nintedanib
- Where
- United States
- Volunteers
- 1,798 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.
- Trial name
- NCT03817463
- Testing
- Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Where
- 13 sites in Denmark, Finland and 9 more
- Volunteers
- 327,624 people
- Sponsor
- Boehringer Ingelheim
Healthy
This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated
The primary objective of this trial is to investigate the safety and tolerability of BI 690517 in healthy Chinese and Japanese male subjects following oral administration of single doses.
- Trial name
- NCT03206632
- Testing
- BI 690517
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathies
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
The primary objective of this current trial is to investigate the safety and tolerability of 3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy as add-on-therapy to Angiotensin Converting…
- Trial name
- NCT03165240
- Testing
- BI 690517, Eplerenone
- Where
- 40 sites in Denmark, France and 8 more
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
Liver Diseases, Healthy
A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems
The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control…
- Trial name
- NCT05731908
- Testing
- BI 690517
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Single Rising Dose Study of BI 690517 in Healthy Volunteers
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses of BI 690517
- Trial name
- NCT02891148
- Testing
- BI 690517
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body
The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.
- Trial name
- NCT05515588
- Testing
- BI 690517 (C-14), BI 690517
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood
The primary objective of the trial is to investigate the safety and tolerability of BI 690517 in healthy male subjects following oral administration of multiple rising doses over 14 days (MRD part).
- Trial name
- NCT03100916
- Testing
- BI 690517, BI 690517 (Reference)
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Non-squamous, Non-Small Cell Lung Cancer
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.
- Trial name
- NCT04750824
- Testing
- Afatinib, other systemic therapy
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body
The main objective of this trial is to select a formulation principle (tablet vs. capsule) and to optimize the identified extended release formulation of BI 894416, if needed.
- Trial name
- NCT04232839
- Testing
- BI 894416 Reference Formulation, BI 894416 Formulation A2, BI 894416 Formulation C2
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis…
- Trial name
- NCT05875532
- Where
- United States
- Volunteers
- 34,960 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
- Trial name
- NCT01734785
- Testing
- Linagliptin, Empagliflozin + Linagliptin
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 607 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors, KRAS Mutation
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
This study is open to Japanese adults with different types of advanced cancer that are positive for NRAS/KRAS mutations. This is a study in people for whom previous treatment was not successful or no standard treatment exists.
- Trial name
- NCT04742556
- Testing
- BI 3011441
- Where
- 3 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
This study is open to adults who have kidney disease that is not caused by diabetes. The purpose of the study is to find out whether a medicine called avenciguat (BI 685509) improves kidney function.
- Trial name
- NCT04736628
- Testing
- Avenciguat
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.